Regulatory decisions made by the Food and Drug Administration (FDA) often serve as important catalysts for pharmaceutical stocks. In the following video, health-care analyst Max Macaluso discusses three upcoming FDA decisions -- on drugs developed by pharma giant Merck (NYSE:MRK), GlaxoSmithKline (NYSE:GSK), and needle-free injection pioneer Antares Pharma (NASDAQ:ATRS) -- and why investors need to keep a close watch on the outcomes of these decisions.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Is Eli Lilly and Company a Buy in 2018?
The outlook is complicated for this big pharma stock.
Why Avon Products Stock Plunged 57% in 2017
Investors punished shares of the direct selling giant as its turnaround plan stalled.
3 Dividend Stocks to Buy for 2018
Here are three names that look cheap right now.